Raykov, Zahary <br/><br/>
Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy.  [electronic resource] 

 -  International journal of cancer  Jun 2014 
 - 2572-82 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1097-0215 
<br/><br/><label>Standard No.: </label>10.1002/ijc.28597  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antimetabolites, Antineoplastic--therapeutic use<br/>Apoptosis--drug effects<br/>Blotting, Western<br/>Cell Proliferation--drug effects<br/>Deoxycytidine--analogs & derivatives<br/>Drug Synergism<br/>Fluorescent Antibody Technique<br/>Humans<br/>Hypoxia--drug therapy<br/>Hypoxia-Inducible Factor 1, alpha Subunit--antagonists & inhibitors<br/>Inositol Phosphates--therapeutic use<br/>Liver Neoplasms--drug therapy<br/>Male<br/>Mice<br/>Mice, Inbred NOD<br/>Mice, SCID<br/>Neovascularization, Pathologic<br/>Oxygen--metabolism<br/>Pancreatic Neoplasms--drug therapy<br/>RNA, Messenger--genetics<br/>Rats<br/>Rats, Inbred Lew<br/>Real-Time Polymerase Chain Reaction<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Tumor Cells, Cultured<br/>Gemcitabine